MedTrace Logo

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

NCT01535157 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-08-27

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma. In addition, researchers would like to determine if the drugs are most effective together or if fenretinide (4-HPR/LXS) is most effective alone.

Conditions

Interventions

DRUG

Fenretinide/LXS + Ketoconazole

Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day

Sponsors & Collaborators

  • South Plains Oncology Consortium

    lead NETWORK

Principal Investigators

  • Jayanthi Lea, MD · University of Texas Southwestern Medical Center

  • Barry J Maurer, MD, PhD · Texas Tech University Health Sciences Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01535157 on ClinicalTrials.gov